Economic evaluation of fi rst-line pd-(l)1 inhibitors for treating non-squamous non-small cell lung cancer in china: a cost-effectiveness analysis based on network meta-analysis

HIGHLIGHTS

• who: March et al. from the Bayer, Germany Sichuan University, China have published the Article: Economic evaluation of fi rst-line PD-(L)1 inhibitors for treating non-squamous non-small cell lung cancer in China: A cost-effectiveness analysis based on network meta-analysis, in the Journal: (JOURNAL) of 20/Oct/2022
• what: As to interventions, the authors focused on approved or proposed first-line combinations of PD-(L)1 blockers and chemotherapy for nsqNSCLC patients in China. The reliability of the study results will be tested if head-to-head RCTs are conducted . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.